TheraRadar
← Back
Data updated: Jun 28, 2026

AJANTA PHARMA LTD

Generics

AJANTA PHARMA LTD is a generic drug manufacturer focused on Neurology, Cardiovascular, Gastroenterology.

2011
Since
63
Drugs
-
Trials
2
New Drugs (2yr)
Modality:

AJANTA PHARMA LTD's Key Drugs

AJANTA PHARMA LTD's core commercial portfolio centers on NAPROXEN AND ESOMEPRAZOLE MAGNESIUM, AMLODIPINE AND OLMESARTAN MEDOXOMIL, SITAGLIPTIN AND METFORMIN HYDROCHLORIDE, spanning Neurology and Cardiovascular — its most strategically important drugs approved in the last 15 years.

AJANTA PHARMA LTD's Therapeutic Areas

AJANTA PHARMA LTD's approved drugs and pipeline span 5 therapeutic areas, led by Neurology and Cardiovascular, across 0 biologic and 0 small-molecule drugs. Weighted by commercial stage — approved drugs count most, then late-stage trials.

Neurology 41%
9 drugs
Cardiovascular 23%
5 drugs
Gastroenterology 14%
3 drugs
Infectious Disease 14%
3 drugs
Ophthalmology 9%
2 drugs

AJANTA PHARMA LTD's Top Competitors

AJANTA PHARMA LTD's closest competitors by therapeutic-area and drug-target overlap include AbbVie, WARNER CHILCOTT, and B BRAUN. Ranked by overlap in therapeutic areas and drug targets across approved drugs and pipeline.

AJANTA PHARMA LTD Pipeline Snapshot

Active clinical trials for AJANTA PHARMA LTD across all therapeutic areas, from ClinicalTrials.gov.

No active pipeline data available

Pro Intelligence Preview

Deep insights for investors and analysts

Revenue Insights

  • NAPROXEN AND ESOMEPRAZOLE MAGNESIUM leads revenue
  • 3 key drugs tracked

Trial Catalysts

  • Neurology pipeline focus
  • Phase 3 readout tracking

Patent Risk

  • Patent expiration timeline
  • Revenue at risk analysis

Compare Companies

  • Side-by-side pipeline analysis
  • Revenue & market share comparison
Unlock Full Intelligence

Revenue forecasts • Trial milestones • Patent risk modeling